14 results
To confirm the efficacy of liraglutide as adjunct to insulin treatment on glycaemic control, and toconfirm the superiority of liraglutide treatment compared to placebo, both adjunct to insulintreatment, with regard to reduction in daily insulin dose…
Primary Objectives•To assess and compare the efficacy of five doses of HM11260C (once weekly subcutaneous injections) over the 12 weeks from baseline in comparison with placebo (once weekly subcutaneous injections) on glycaemic control, as assessed…
1. To assess the efficacy of liraglutide in patients with schizophrenia and diabetes ona. Glycaemic controlb. Body weightc. Cardiovascular risk factors (blood pressure, lipids)2. To assess the safety of liraglutide in these patients3. To assess the…
1. Overall survival (primary efficacy endpoint)2a. Efficacy: progression-free survival (PFS), overall response rate (ORR = CR + PR), and a clincal benefit rate (CBR) will be evaluated as CR + PR + SD for at least 3 months.2b. Safety: adverse events…
To confirm superiority of liraglutide compared to placebo, both adjunct to insulin treatment, on glycaemic control, after 26 weeks of treatment in subjects with established type 1 diabetes in inadequate glycaemic control.
Primary objectiveTo confirm the superiority of liraglutide at the maximum tolerated dose (0.6 mg, 1.2 mg or 1.8 mg) versus placebo when added to metformin with or without basal insulin treatment in controlling glycaemia in children and adolescents (…
This study investigates the optimal intraoperative treatment algorithm to lower glucose in patients with diabetes mellitus type 2 undergoing non-cardiac surgery, comparing intraoperative glucose-insulin-potassium infusion, insulin bolus regimen and…
The aim of this study is to investigate whether a mobile telemonitoring guided CR (mCR) as alternative for a regular CR programme is an effective means to increase participation and adherence of elderly in a CR programme, and results in better long…
Primary objective:To assess the effect of treatment with liraglutide compared to placebo for at least 3.5 yearand up to 5 years on the incidence of cardiovascular events, as defined by the belowprimary and secondary endpoints, in adults with type 2…
the purpose of this study is to investigate the efficacy of liraglutide to lower glucose and to influence coagulation activation during and after hip surgery
To confirm superiority on glycaemic control of liraglutide versus placebo after 26 weeks of treatment when added to pre-existing basal insulin analogue treatment (with or without concomitant metformin treatment) in subjects with type 2 diabetes.
The primary objective of this study is to demonstrate the superiority of insulin glargine over liraglutide in termsof percentage of patients reaching a HbA1c < 7% at the end of the comparative period in Type 2 diabetic patientsfailing…
Study 1:1) To test the hypothesis that Liraglutide improves cardiovascular function in DM2 patients and whether the improvement is associated with redistribution of ectopic fat stores. 2) To test the hypothesis that Liraglutide activates BAT in DM2…
We hypothesize that liraglutide treatment (a GLP-1 analogue), initiated before cardiac surgery, is effective in lowering the number of patients needing perioperative insulin adjustments and reducing the total amount of insulin needed in the…